Performance & Efficacy of the CardiacSense1 for Detection of Atrial

Status Completed

Clinical Trial Summary

A Prospective, Open, Multi-Center, Controlled Study to Evaluate the Safety, Performance and Efficacy of the CardiacSense1 for Detection of Atrial Fibrillation.

The clinical study is intended to establish the efficacy and safety of the CardiacSense1 wearable device intended to monitor and detect heart arrhythmia, specifically atrial fibrillation (A-Fib) based on a comparison to a control device, which is an off-the-shelf cleared Holter ECG device

Clinical Trial Description

The clinical study is intended to establish the efficacy and safety of the CardiacSense1 wearable device intended to monitor and detect heart arrhythmia, specifically atrial fibrillation (A-Fib). Study design as as follows:

100 subjects, 50 (at least 30% of each gender) with A-fib and 50 without (at least 30% of each gender).

All subjects will be measured during at least 24 hours. Primary endpoint - A-Fib detection Control: Holter device will be the reference

For PPG analysis, each one hour will be considered as an event:

If A-Fib is present for more than accumulated 5 minutes in that specific hour then it shall be considered an "A-Fib hour" If A-fib was present for less than accumulated 5 minutes then it shall be considered a "Non-A-Fib hour".

For ECG analysis, each measurement of between 1-3 minutes will be considered an event.

If A-Fib is present at that specific measurement, then it shall be considered an "A-Fib event" If A-fib was not present at that specific measurement, then it shall be considered a "Non-A-Fib hour".

Sensitivity (true positive) is defined as the percentage of Holter defined "A-fib hours"/"A-Fib event" found by PPG/ECG.

The asked sensitivity is 90%. Specificity (true negative) is defined as the percentage of Holter defined "Non-A-fib hours"/"A-Fib event" found by PPG/ECG. The required specificity is 90%. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03477734
Study type	Interventional
Source	CardiacSense Ltd.
Contact
Status	Completed
Phase	N/A
Start date	February 20, 2019
Completion date	June 9, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05434650` - Abbott Atrial Fibrillation Post Approval Study
Completed	`NCT02949180` - Enhanced Diagnostics for Early Detection of Atrial Fibrillation - Prospective Validation	N/A
Recruiting	`NCT05633303` - Personalised Ablation Strategies in AF	N/A
Completed	`NCT04293198` - Evaluating the Performance of the KODEX-EPD CRyOballoon Occlusion Feature in Patients With Atrial Fibrillation
Not yet recruiting	`NCT05973474` - The Atherogenic Index of Plasma（AIP） in Patients With Atrial Fibrillation
Not yet recruiting	`NCT06402851` - Vitamin K AntagonISt, Factor Xa Inhibitor Or Nothing In Atrial Fibrillation And DIalytic End-stage Renal DiseasE (VISIONAIRE)	Phase 4
Not yet recruiting	`NCT06165510` - Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation	N/A
Recruiting	`NCT05456204` - Refralon in Patients With Recurrence Paroxysmal and Persistent Forms of Atrial Fibrillation Who Underwent Catheter Ablation	N/A
Recruiting	`NCT04545437` - The Short and Long-term Cardiovascular Consequences of Critical Illness: The C3 Study
Recruiting	`NCT03487419` - Echocardiographic Left Atrial Function Assessment and Atrial Fibrillation Post-Coronary Artery Bypass Surgery